Fig. 1: Time-to-event outcomes in GO- vs. non-GO-treated patients. | Leukemia

Fig. 1: Time-to-event outcomes in GO- vs. non-GO-treated patients.

From: Gemtuzumab ozogamicin in first-line treatment of CBF-AML: insights from a retrospective multi-center analysis

Fig. 1

The addition of GO was associated with significantly improved OS (A) and EFS (B). CIR was numerically lower in GO-treated patients compared to those who did not receive GO (C), although the difference did not reach statistical significance. GO gemtuzumab ozogamicin, HR hazard ratio, CI confidence interval.

Back to article page